Human Immunology News Volume 10.37 | Sep 20 2022

September 20, 2022

2022-09-20 | HIN 10.37

Human Immunology News by STEMCELL Technologies

Vol. 10.37 – 20 September, 2022

TOP STORY

Cancer Cell Autophagy, Reprogrammed Macrophages, and Remodeled Vasculature in Glioblastoma Triggers Tumor Immunity

Researchers combined vascular endothelial growth factor (VEGF) pathway inhibitors that remodel the tumor vasculature with the tricyclic antidepressant imipramine, which enhanced autophagy in glioblastoma cancer cells and unexpectedly reprogrammed immunosuppressive tumor-associated macrophages.
[Cancer Cell]

Full Article Graphical Abstract

Enter for a chance to win refreshments for your immunology journal club.

PUBLICATIONSRanked by the impact factor of the journal

CAR-T Cell Therapy-Related Cytokine Release Syndrome and Therapeutic Response Is Modulated by the Gut Microbiome in Hematologic Malignancies

Scientists showed that the gut flora characteristically differed among CAR-T therapy patients and according to treatment stages, and might have also reflected patient response to therapy in relapsed/refractory multiple myeloma, acute lympholastic leukemia, and non-Hodgkin lymphoma.
[Nature Communications]

Full Article

Therapeutic High Affinity T Cell Receptor Targeting a KRASG12D Cancer Neoantigen

The authors showed the identification and development of an affinity-enhanced T cell receptor that recognized a peptide derived from the most common KRAS mutant, KRAS^G12D, presented in the context of HLA-A*11:01.
[Nature Communications]

Full Article

Decidual Dendritic Cells 10 and CD4+MCD25+FOXP3 Regulatory T Cell in Preeclampsia and Their Correlation With Nutritional Factors in Pathomechanism of Immune Rejection in Pregnancy

Researchers conducted a cross-sectional study among early onset preeclampsia, late onset preeclampsia, and normotensive pregnancies. The number of decidual dendritic cell-10 and Treg cells were counted using flow cytometry.
[Journal of Reproductive Immunology]

Abstract

Cytotoxic CD8+ T Cells May Be Drivers of Tissue Destruction in Sjögren’s Syndrome

Quantitative analyses of CD4⁺ T cell subsets and of CD8⁺ T cells in the labial salivary glands from untreated patients with primary Sjögren’s syndrome revealed that activated CD8⁺ cytotoxic T cells were the most prominent T cells in these infiltrates.
[Scientific Reports]

Full Article

A LILRB1 Variant with a Decreased Ability to Phosphorylate SHP-1 Leads to Autoimmune Diseases

Investigators identified the causative variant in a three-generation family with nine members suffering from one of the three autoimmune diseases — Graves’ disease, Hashimoto’s thyroiditis, or systemic lupus erythematosus.
[Scientific Reports]

Full Article

The Proportion and Phenotypic Changes of CD4⁺CD25⁻Foxp3⁺ T Cells in Patients with Untreated Rheumatoid Arthritis

Scientists investigated the frequency of circulating CCD4⁺CD25⁻Foxp3⁺ Treg cells and their role in rheumatoid arthritis.
[BMC Immunology]

Abstract

CD8⁺ and FoxP3⁺ T-Cell Cellular Density and Spatial Distribution after Programmed Death-Ligand 1 Check Point Inhibition

The authors analyzed CD8⁺ and FoxP3⁺ T cell cellular density and intercellular distances in head and neck squamous cell carcinoma samples from a neoadjuvant trial of durvalumab^+/− metformin.
[Laryngoscope]

Abstract

Learn about immunological considerations for hPSC banking by watching Dr. David Turner's webinar from the Nature Research Round Table on hPSC Quality

REVIEWS

Resident Cardiac Macrophages: Heterogeneity and Function in Health and Disease

Investigators review recent progress on resident cardiac macrophage heterogeneity, origins, and functions to either directly or indirectly influence cardiac physiology through orchestrating multi-cellular communication with cardiomyocytes, stromal, and immune populations.
[Immunity]

Abstract

Emerging Concepts of Type I Interferons in SLE Pathogenesis and Therapy

Evidence relating to biomarkers to characterize the type I interferon system is complex, and, notably, interferon-blocking therapies are now licensed for the treatment of systemic lupus erythematosus (SLE).
[Nature Reviews Rheumatology]

Abstract

Therapeutic Targets and Biomarkers of Tumor Immunotherapy: Response Versus Non-Response

Immune checkpoint blocking therapy, represented by PD-1/PD-L1 inhibitors and CTLA-4 inhibitors, has shown encouraging therapeutic effects in the treatment of various malignant tumors, such as non-small cell lung cancer and melanoma.
[Signal Transduction and Targeted Therapy]

Full Article

INDUSTRY AND POLICY NEWS

aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-Ild)

aTyr Pharma, Inc. announced that the US FDA has granted the company Fast Track designation for its lead therapeutic candidate, efzofitimod, for the treatment of SSc-Ild.
[aTyr Pharma, Inc.]

Press Release

Virogin Biotech and MD Anderson Announce Strategic Collaboration to Accelerate Oncolytic Virus Research and Development for Treating Advanced Cancers

Virogin Biotech and The University of Texas MD Anderson Cancer Center announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.
[Virogin Biotech (Globe Newswire, Inc.)]

Press Release

FEATURED EVENT

Human Immunology News Volume 10.37 | Sep 20 2022

Cancer Cell Autophagy, Reprogrammed Macrophages, and Remodeled Vasculature in Glioblastoma Triggers Tumor Immunity

CAR-T Cell Therapy-Related Cytokine Release Syndrome and Therapeutic Response Is Modulated by the Gut Microbiome in Hematologic Malignancies

Therapeutic High Affinity T Cell Receptor Targeting a KRASG12D Cancer Neoantigen

Decidual Dendritic Cells 10 and CD4+MCD25+FOXP3 Regulatory T Cell in Preeclampsia and Their Correlation With Nutritional Factors in Pathomechanism of Immune Rejection in Pregnancy

Cytotoxic CD8+ T Cells May Be Drivers of Tissue Destruction in Sjögren’s Syndrome

A LILRB1 Variant with a Decreased Ability to Phosphorylate SHP-1 Leads to Autoimmune Diseases

The Proportion and Phenotypic Changes of CD4⁺CD25⁻Foxp3⁺ T Cells in Patients with Untreated Rheumatoid Arthritis

CD8⁺ and FoxP3⁺ T-Cell Cellular Density and Spatial Distribution after Programmed Death-Ligand 1 Check Point Inhibition

Resident Cardiac Macrophages: Heterogeneity and Function in Health and Disease

Emerging Concepts of Type I Interferons in SLE Pathogenesis and Therapy

Therapeutic Targets and Biomarkers of Tumor Immunotherapy: Response Versus Non-Response

aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-Ild)

Virogin Biotech and MD Anderson Announce Strategic Collaboration to Accelerate Oncolytic Virus Research and Development for Treating Advanced Cancers

Cell Symposia: Multifaceted Mitochondria

> See All Events

Postdoctoral Researcher – Bioinformatics, mRNA Translation in Cancer

Research Associate – Cancer Immunotherapy

Postdoctoral Fellow – Immunobiology and Microbial Pathogenesis

Assistant/Associate Professor – Comparative Biomedical Science

Postdoctoral Research Associate – Department of Cardiothoracic and Vascular Surgery

> See All Jobs